Ticker: RXRX | Published: 2026-09-21
AI drug platform buzz
Recursion is rallying violently on renewed attention to its AI-driven drug discovery platform, with the move amplified by the stock's small float and heavy retail interest even as volume stays near normal.
Sources: https://finance.yahoo.com/healthcare/articles/recursion-pharmaceuticals-highlights-ai-drug-010200541.html